

ADLER, ROBERT A. Chief, Endocrinology and Metabolism, McGuire Veterans Affairs Medical Center; Professor of Internal Medicine, Professor of Epidemiology and Community Health, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA

Place of Birth: Somerville, New Jersey, USA

Education/Training/Positions: Franklin & Marshall College, Lancaster, Pennsylvania, 1963-65; BA, Johns Hopkins University, Baltimore, Maryland, 1967; MD, Johns Hopkins University School of Medicine, 1970; Intern and Resident, Internal Medicine, Johns Hopkins Hospital, 1970-1972; Fellow in Endocrinology, Massachusetts General Hospital, Boston, Massachusetts,

1972-73; Fellow in Endocrinology, Walter Reed Army Medical Center, Washington, DC, 1973-74; Assistant Chief, Endocrinology and Clinical Investigator, Fitzsimons Army Medical Center, Denver, Colorado, 1974-76; Clinical Instructor in Medicine, University of Colorado, Denver, Colorado, 1975-76; Assistant Professor and Associate Professor of Medicine, Dartmouth Medical School, Hanover, New Hampshire, 1976-84; Staff Endocrinologist, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, 1976-84; Consultant, Endocrinology, White River Junction Veterans Affairs Medical Center, White River Junction, Vermont, 1976-84; Associate Professor and Professor of Internal Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, 1984-present; Professor of Epidemiology and Community Health, Virginia Commonwealth University School of Medicine, 2002-present; Assistant Chief, Endocrinology, McGuire Veterans Affairs Medical Center, Richmond, Virginia, 1984-1985; Chief, Endocrinology and Metabolism, McGuire Veterans Affairs Medical Center, 1985-present

Honors/Awards: Teaching Award, Dartmouth Medical School, 1984; Teaching Award, Medical College of Virginia, Virginia Commonwealth University, 1998-1999; Irby-James Award for Excellence in Clinical Teaching, Virginia Commonwealth University, 2004

Editorial Duties/Peer Review Panels: Editorial Boards: *Journal of Clinical Endocrinology and Metabolism*, 1988-1992; *Journal of Clinical Densitometry*, 1997-present; *American Journal of Physiology*, Endocrinology Section, 1998-2001; Endocrine Research, 2008-present; *Journal of Bone and Mineral Research*, 2009-present; Editor, *Osteoporosis – Pathophysiology and Clinical Management*, 2nd Edition; Reviewer for 40 journals; Review Panels: Ad hoc reviewer, Department of Veterans Affairs Merit Review Program; March of Dimes Grant Program; American Federation for Aging Research; Spinal Cord Foundation; Jeffress Foundation;; MayDay Foundation; Department of Veterans Affairs Cooperative Studies Program; NIH Study Sections-Prevention of Osteoporosis, DDK-B Subcommittee, Skeletal Biology Structure and Regeneration, NIAMS Special Emphasis Panel; Ad hoc reviewer, NIH Skeletal Biology and Development and Disease, 2003-present; US Army Medical Research and Materiel Command Congressionally Directed Medical Research Program, 2009; Pre-Reviewer, Endocrinology Specialty Programs, Accreditation Council for Graduate Medical Education, 1994-1998; Endocrinology Subspecialty Appeals Panel, Accreditation Council for Graduate Medical Education, 2000-present; Osteoporosis Working Group, American Medical Association, Physician Consortium for Performance Improvement, 2006-2007; Chair, Department of Veterans Affairs Male Osteoporosis Technical Advisory Panel, 2007-present; Endocrinology and Diabetes Field Advisory Committee, Department of Veterans Affairs, 2008-present; American College of Rheumatology Glucocorticoid-Induced Osteoporosis Guidelines Task Force, 2009-present

Professional Societies: Membership: ASBMR, 1986-present; American Association for the Advancement of Science; Endocrine Society; Southern Society for Clinical Investigation; Pituitary Society; Fellow, American College of Physicians; International Bone and Mineral Society; International Society for Clinical Densitometry (ISCD); Scientific Advisory Committee, ISCD, 2003-present; Chair and member, ASBMR Professional Practice Committee, 2004-present; Ex Officio Member, ASBMR Science Policy Committee, 2007-present; Member, ASBMR Clinician Outreach Task Force, 2009; Co-Chair, Task Force on ASBMR-Industry Interactions, 2009; ASBMR Subtrochanteric Fracture Task Force 2009-present; ASBMR-NOF Liaison Group 2009-present; ASBMR representative to Endocrine Society Male Osteoporosis Guidelines Committee, 2009-present

Current Research: Screening for osteoporosis in men; bone mineral density testing in men; osteoporosis in men on androgen deprivation therapy for prostate cancer; muscle strength, balance, and osteoporosis in Parkinson's disease; interventions to improve management of glucocorticoid-induced osteoporosis; body composition changes and osteoporosis management in spinal cord injury; use of electronic medical records and decision support to improve osteoporosis management; male hormone replacement therapy; osteoporosis diagnosis and management in the Department of Veterans Affairs; pituitary dysfunction after traumatic brain injury.

Statement of Interest: I didn't become deeply interested in mineral metabolism until my basic research on prolactin led to studies of the association of hyperprolactinemia with osteoporosis. During a later career transition from basic to clinical research I found that little was known about osteoporosis in men, and I have devoted the last 15 years trying to add to our knowledge base. I founded a Metabolic Bone Disease Clinic at my Veterans Affairs Medical Center. As male osteoporosis became better recognized, the clinic has become very busy. It is a major teaching clinic, the only one where our students, residents, fellows, and pharmacy residents can learn about metabolic bone diseases. I continue to study male osteoporosis and was an invited speaker at

the recent NOF International Symposium on Osteoporosis. I serve as Chair of the Male Osteoporosis Technical Advisory Panel for the Department of Veterans Affairs. We have prepared an osteoporosis management algorithm that has been distributed to all V.A. medical centers.

Some years ago I applied for a position on the Professional Practice Committee, and after a few tries was nominated. As I became very involved with the work of the committee, I eventually became its chair, a job that has carried significant responsibility and a lot of work – but it has also been a great pleasure and privilege. The PPC has dealt with many topics such as the new NOF Guidelines, complications of osteoporosis treatment, reimbursement for DXA and vitamin D measurements, performance measures, and the FRAX. The discussions have been intellectually stimulating, and the PPC has contributed to assuring quality in medical practice. I have had the privilege of moderating important clinical sessions at the annual meeting, based on contentious clinical issues – and hope to do so again in 2010. My status as a salaried V.A. employee gives me a more objective perspective on such clinical issues as DXA reimbursement. I have read 10,000 DXAs but receive no direct compensation for it. Thus on reimbursement issues, I have no potential conflicts. I have both investigator-initiated and pharmaceutical research funds. I continue to consult for a few companies because my expertise can be used to further patient care this way. I have been on speakers' bureaus, but I just turned one offer down because there was no "academic freedom." All of my talks could be given at CME sessions.

Serving on Council would utilize my experience as PPC Chair and help with continuing and future issues. As US medicine is "reformed," there will be many challenges. We can learn from other countries, from the "socialized" system I have worked in, and from the many PPC discussions. It would be a great honor to continue my work this way, based on basic science, clinical research, clinical practice, teaching, and committee experience. I have enjoyed and learned much working with my ASBMR colleagues and the ASBMR staff. I believe that I can make further contributions to the organization and to medical science.

Disclosures: Amgen 1; Eli Lilly and Co. 1, 2; Genentech 1; GTx, Inc. 2; Merck & Co., Inc. 2; Novartis 1, 3; Procter & Gamble 1; ISCD 6 (Scientific Advisory Committee); *Endocrine Research* 6 (Editorial Board); *Journal of Clinical Densitometry* 6 (Editorial Board)

The following numerical key was used to characterize the potential conflicts of interest listed in the "Disclosures" section above.

1. *research grants or financial support from commercial entities*
2. *consultant or member of advisory board to a commercial entity*
3. *participant in a speakers bureau*
4. *employment or executive positions in pharmaceutical, medical device, or diagnostic companies*
5. *stock holdings in pharmaceutical, medical device, or diagnostic companies*
6. *any other situation or transaction in relation to the ASBMR in which a formal role or interest exists (e.g., candidate is a member of another bone-related organization's board, or committee, or serves on its journal, etc.)*



ARNOLD, ANDREW Murray-Heilig Chair in Molecular Medicine, Professor of Medicine and Genetics, University of Connecticut School of Medicine, Farmington, Connecticut, USA

Place of Birth: New York, New York, USA

Education/Training/Positions: ScB, Brown University, Providence, Rhode Island, 1974; MD, Harvard Medical School, Boston, Massachusetts, 1978; Resident in Internal Medicine, University of Chicago, Chicago, Illinois, 1978-1981; Medical Staff Fellow, National Cancer Institute, Bethesda, Maryland, 1981-1984; Clinical and Research Fellow in Medicine (Endocrinology), Massachusetts General Hospital, 1984-1986; Instructor in Medicine, Assistant Professor and

Associate Professor, Harvard Medical School and Endocrine Unit, Massachusetts General Hospital, 1985-1997; Chief, Laboratory of Endocrine Oncology, Massachusetts General Hospital, 1992-1997; Murray-Heilig Chair in Molecular Medicine, Professor of Medicine, Professor of Genetics and Developmental Biology, University of Connecticut School of Medicine, 1997-present; Director, Center for Molecular Medicine, Chief, Division of Endocrinology and Metabolism, University of Connecticut School of Medicine, 1997-present

Honors/Awards: Fuller Albright Award, ASBMR, 1992; American Society for Clinical Investigation, elected 1993; Outstanding Investigator Award, APCR/AFMR, 1995; Association of American Physicians, elected 1996; Gerald D. Aurbach Award, The Endocrine Society, 2001; John G. Haddad, Jr. Research Award, The Paget Foundation, 2001; Eli Lilly Award Lecture, Canadian Society of Endocrinology & Metabolism, 2006; Louis V. Avioli Founder's Award, ASBMR, 2006

Editorial Duties/Peer Review Panels: Editorial Boards: *Endocrinology*, 1993-1996; *Journal of Endocrinological Investigation*, 1996-1999; *Journal of Endocrine Genetics*, 1999-2006; *Endocrine Reviews*, 2006-present; *Clinical and Translational Science*, 2007-present; Scientific Advisory Committee, Third International Conference on New Actions of Parathyroid Hormone, Kyoto, Japan, 1994; Scientific Advisory Committee, International Symposium on Thyroid and Parathyroid Neoplasia, Pisa, Italy, 1999; Associate Editor, *Journal of Clinical Endocrinology & Metabolism*, 2000-2004; Editor, Parathyroid and Bone Disease Section, ENDOTEXT.ORG, 2000-2008; Endocrinology Evaluation Board, *Faculty of 1000 Medicine, Bone and Mineral Metabolism Section*, 2005-2007; Research Program Review Panel, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, 2008; Co-Chair, Biomedical Peer Reviewers, State of Connecticut Biomedical Grants-in-Aid Program, 2009

Professional Societies: Scientific and Educational Program Committee, Endocrine Society, 1995-1998; Annual Meeting Steering Committee, Endocrine Society, 1996-1998; Publications Committee, ASBMR, 1996-1999; ASBMR Council, 1999-2002; Annual Meeting Steering Committee, Endocrine Society, 2000-2002; Nominating Committee, ASBMR, 2000-2001; Chair, Task Force on Young Investigator Awards, ASBMR, 2000-2001; Meetings and Educational Programs Committee, Endocrine Society, 2001-2002; Basic Science Chair, Annual Meeting, Endocrine Society, 2002; Council, Association of Program Directors in Endocrinology & Metabolism, 2003-2005; Basic Science Chair, Annual Meeting, ASBMR, 2006; Presidential Liaison, Young Investigator Awards, ASBMR, 2002-present

Current Research: Molecular pathogenesis of tumors of endocrine glands with emphasis on parathyroid tumorigenesis; Mechanism of action of the cyclin D1 oncogene in parathyroid and non-parathyroid neoplasia; Role of HRPT2/CDC73/parafibromin in sporadic and familial parathyroid carcinoma, including implications for clinical management; Animal modeling of primary hyperparathyroidism, including study of the impact of vitamin D deficiency on parathyroid tumorigenesis

Statement of Interest: Throughout my career the ASBMR has been my primary "home" professional society, and I owe a tremendous debt of gratitude for all the ways I've benefited from society activities over these 2+ decades. These include the fact that so many of my most valued professional relationships and friendships have been initiated and fostered through ASBMR. Further, it has been a privilege to serve the Society in multiple capacities including committee memberships co-chairing the Annual Meeting and serving on Council. Being very cognizant of the time and effort required to effectively serve the Society at the leadership level, I now feel (for the first time) able to make the enhanced commitment to serve the ASBMR as President-Elect and President and would welcome this opportunity if the Nominating Committee and voting membership are so inclined. Thank you for your consideration of this statement of interest and commitment.

Disclosures: *Endocrine Reviews* 6 (Editorial Board)

The following numerical key was used to characterize the potential conflicts of interest listed in the "Disclosures" section above.

1. research grants or financial support from commercial entities
2. consultant or member of advisory board to a commercial entity
3. participant in a speakers bureau
4. employment or executive positions in pharmaceutical, medical device, or diagnostic companies
5. stock holdings in pharmaceutical, medical device, or diagnostic companies
6. any other situation or transaction in relation to the ASBMR in which a formal role or interest exists (e.g., candidate is a member of another bone-related organization's board, or committee, or serves on its journal, etc.)



BOYCE, BRENDAN F. Professor, University of Rochester Medical Center, Rochester, NY, USA

Place of Birth: Coatbridge, Scotland, United Kingdom

Education/Training/Positions: M.B. Ch.B., University of Glasgow Medical School, Scotland, 1966-1972; Member, Royal College of Pathologists (MRCPATH), United Kingdom, 1979; Fellow of the Royal College of Pathologists (FRCPath), United Kingdom, 1991; Resident House Officer in Gen. Medicine, Western Infirmary, Glasgow, and in Gen. Surgery, Royal Infirmary, Glasgow, 1972-73; Senior House Officer and Registrar in Pathology, Royal Infirmary, Glasgow, 1973-76; Lecturer in Pathology, Department of Pathology, University of Glasgow, 1976-85; Peel International Research Fellow and Visiting Professor of Medicine, Division of Endocrinology University of Texas Health Science Center, San Antonio, TX (UTHSCSAT), 1986-88; Senior Lecturer, University of Glasgow, 1985-90; Associate Professor and Professor, Department of Pathology, UTHSCSAT, 1990-1999; Professor, Department of Pathology and Laboratory Medicine and Department of Orthopaedics, University of Rochester, New York, 1999-present

Honors/Awards: Jean Mackintosh Traveling Research Fellowship (Scotland), 1977; McCunn Trust Traveling Fellowship (Scotland), 1986-87; Pathological Society Travel Award (England), 1986-87; Peel International Research Fellowship (England), 1986-87; Most Outstanding Abstract of the Meeting President's Award from ASBMR, 1997; President, International Society of Bone Morphometry (ISBM), 2002-2006; Secretary/Treasurer, Association of Osteobiology, 2003-2006; Vice Chair and Chair, Gordon Research Conference on Bones and Teeth, 2007, 2009, respectively

Editorial Duties/Peer Review Panels: Consulting Editor, *Journal of Clinical Investigation*, 2008-present; Editorial Board: *JBM*, 2004-Present; *Calcified Tissue International*, 2000-2002; *Endocrinology*, 1998-2002, 2005-2009; NIH Study Section panels: Orthopaedic, 2003; Otolaryngology, 2005; NCI, 2006; National Center for Complimentary and Alternative Medicine, 2007; Chair, Musculoskeletal, Oral, and Skin Sciences Integrated Review Group (MOSS IRG) Special Emphasis Panel, 2008-2009; Member: Skeletal Biology Structure & Regeneration (SBSR), 2008-2009; Musculoskeletal, Oral, and Skin Sciences Integrated Review Group (MOSS IRG) STTR, 2008; Reviewer: NASA; American Cancer Society; Veterans Administration (USA); Wellcome Research Trust, England; Medical Research Council of Great Britain; Medical Research Council of Canada; The Patrick and Catherine Weldon Donaghue Medical Research Foundation; Arthritis Research Campaign, United Kingdom; Arthritis Rheumatism Council, United Kingdom; Australian National Health Medical Research Council; Austrian Science Fund

Professional Societies: Royal College of Pathologists, 1979-present; ASBMR, 1987-present; ISBM, 1993-present; IBMS, 1994-present; NYAS, 2005-present; Vice Chair, Scientific Review Committee, ISBM, 2008; Member, Scientific Program Committee, European Calcified Tissue Society, 2006-present; Member, Scientific Advisory Committee, 1st Asian Pacific Congress on Bone Morphometry, 2004; Member, Scientific Program Committee, Orthopaedic Research Society, 2003-2006; Member, Education Committee, ASBMR, 2003-2006; Council Member, Association of Osteobiology, 2001-2007; Member, Scientific Program Committee, ISBM IXth Congress, 2002-present; Board Member, ISBM, 1999-present; Member, Scientific Program Committee, ASBMR, 1991-2007; ; Member, Scientific Program Committee, European Calcified Tissue Society, 2004-Pres; Trustee, Biological Stain Commission, 2009-present;

Current Research: Study of the effects of cytokines, including TNF, RANKL and IL-1, and role the transcription factors, NF- κ B, c-Fos and NFATc1 in osteoclast formation, activation and survival, with emphasis on canonical and non-canonical NF- κ B signaling pathways; the role of SRC tyrosine kinase in osteoclast and osteoblast activity and of the efficacy of SRC inhibitors in prevention of metastatic cancer-induced osteolysis in animal models of metastatic bone disease; NF- κ B and RANK signaling in endochondral ossification.

Statement of Interest: I have been a member of ASBMR since 1987, a year after I went on Sabbatical as the Peel International Research Fellow to Greg Mundy's lab in San Antonio to learn to do basic research, having spent 10 years in Scotland doing clinical bone research and bone histomorphometry with Iain Boyle and colleagues in Glasgow. My research has focused on osteoclast biology using animal models of common bone diseases. My research highlights include: discovery that Src tyrosine kinase expression is required for osteoclast ruffled border formation; that osteoclasts typically die by apoptosis; that bisphosphonates and estrogen induce osteoclast apoptosis and opening the field of apoptosis research to the bone field; that expression of NF- κ B1 and 2 is required for osteoclast and B cell differentiation; and more recently that in addition to stimulating osteoclast formation, TNF limits osteoclastogenesis through the inhibitory effects of NF- κ B3, whose expression TNF up-regulates. I have attended all ASBMR meetings since 1987 and served on the Education Committee 2003-2006. I am the Past-President of the International Society of Bone Morphometry (2002-2006). As such, I organized and raised all of the financial support for the 2006 Congress in Philadelphia, and improved the Society's bank balance significantly. I am Past-Secretary/Treasurer of the Association of Osteobiology (2002-2006) and during that period also improved the Association's financial status such that a reduction in annual dues became possible. Through these activities, I have come to know many leaders in the field as well as numerous rank and file members. I was elected Chair of the 2009 Gordon Research Conference on Bones and Teeth in 2005. I asked a group of leading researchers in the field to become Discussion Leaders and they helped choose outstanding speakers for the Conference. I also wrote several grant applications to NIH and Pharmaceutical companies to support the costs of running the Conference. Thus, I have significant experience raising support for organizations and with the

day to day activities that a Secretary/Treasurer of a Society is engaged in. I am also a practicing clinician as a surgical pathologist at Strong Memorial Hospital and am head of Anatomic Pathology, which has 33 clinical faculty members in several sub-divisions. I am interested in serving the ASBMR further because it plays a key role in pulling together researchers in the musculoskeletal field in the US and throughout the world and representing musculoskeletal research interests in many organizations and forums in the US and elsewhere. Recently, major pharmaceutical companies have been reorganizing and merging. Consequently, we will likely face a period of growing economic challenges for the Society. This will mean more careful planning of future activities and more arduous efforts to raise funds, while still supporting the major educational role the Society plays in fostering the career development of young scientists. I am prepared to devote the time and effort necessary to help meet these challenges, if I am elected Secretary/Treasurer. I will work diligently to help the Society remain the major vehicle driving efforts to grow Government and other support for musculoskeletal research.

Disclosures: Kinex Corporation 2

The following numerical key was used to characterize the potential conflicts of interest listed in the “Disclosures” section above.

- 1. research grants or financial support from commercial entities*
- 2. consultant or member of advisory board to a commercial entity*
- 3. participant in a speakers bureau*
- 4. employment or executive positions in pharmaceutical, medical device, or diagnostic companies*
- 5. stock holdings in pharmaceutical, medical device, or diagnostic companies*
- 6. any other situation or transaction in relation to the ASBMR in which a formal role or interest exists (e.g., candidate is a member of another bone-related organization’s board, or committee, or serves on its journal, etc.)*



EBELING, PETER R. Professor of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.

Place of Birth: Melbourne, Victoria, Australia

Education/Training/Positions: MB, BS, The University of Melbourne, Melbourne, Victoria, Australia, 1980; MD, The University of Melbourne, Melbourne, Victoria, Australia, 1989; FRACP, Royal Australasian College of Physicians, Australia, 1989; Research Fellow, Mayo Graduate School of Medicine and Mayo Foundation, Rochester, Minnesota, 1988-1990; Senior Research Fellow, Mayo Graduate School of Medicine and Mayo Foundation, 1990-1991; D. W. Keir Fellow in Medical Research, Assistant Physician, Bone and Mineral Service, Department of

Diabetes and Endocrinology, The Royal Melbourne Hospital, Parkville, Victoria, Australia, 1991-1994; Clinical Associate Professor, Department of Medicine (RMH/WH), The University of Melbourne, The Royal Melbourne Hospital, 2000-2005; Visiting Academic, Botnar Research Centre, The Oxford University Institute of Musculoskeletal Sciences, Nuffield Orthopedic Centre, Oxford, England, United Kingdom, 2003; Professor of Medicine, Chair, Department of Medicine (RMH/WH), The University of Melbourne, The Western Hospital, Footscray, Victoria, Australia, 2005-present

Honors/Awards: Victorian Postgraduate Medical Foundation Research Scholarship, 1987; Australian National Health and Medical Research Council Postgraduate Scholarship, 1987-88; Advanced Trainee Award, Victorian Branch, Royal Australasian College of Physicians, 1987; Henry and Rachel Ackman Traveling Scholarship, The University of Melbourne, 1988; Mayo Foundation Research Fellowship, 1988-1990; Mayo Foundation Senior Research Fellowship, 1990-1991; Young Investigator Award, Advances in Mineral Metabolism Meeting, Snowmass, Colorado, USA, 1991; D. W. Keir Fellowship in Medical Research, The Royal Melbourne Hospital, Parkville, Victoria, Australia, 1991-1994

Editorial Duties/Peer Review Panels: Editorial Boards: *Journal of Bone and Mineral Research*, 2001-present; *Osteoporosis International*, 2009-present; Associate Editor, *Journal of Bone and Mineral Research*, 2008-present; Member: Panel of Independent Assessors, Australian National Health and Medical Research Council, 1994-present; Grant Review Panel Member, Australian National Health and Medical Research Council, 1999, 2007; Chair, Musculoskeletal Diseases Grant Review Panel, Australian National Health and Medical Research Council, 2008; Member: Australian National Health and Medical Research Council Academy, Musculoskeletal Diseases and Sports Medicine, 2009; Member: National Assessors Panel for Cancer Research Grants, Anti-Cancer Council of Victoria, 2000-present; Medical Research Council of New Zealand, 1999-present; Royal Adelaide Hospital Research Foundation, 1998-present; Western Australian Research Foundation, 1998-present; Cancer Foundation of Western Australia, 1999-present; Medical and Scientific Committee Member, Osteoporosis Australia, 2002-present; Medical Director and Chair, Medical and Scientific Committee Member, Osteoporosis Australia, 2006-present; Co-Chair, Australian Musculoskeletal Quality Improvement Program Advisory Group, 2006-2007

Professional Societies: Membership: ASBMR, 1988-present; Advances in Mineral Metabolism; Endocrine Society; Australian and New Zealand Bone and Mineral Society; Endocrine Society of Australia; International Conference on Calcium Regulating Hormones; International Bone and Mineral Society; Member, Board of National Societies, International Osteoporosis Foundation, 1999-2001; Program Co-Chair, ASBMR 31st Annual Scientific Meeting, 2009; Member: ASBMR Task Forces on Osteonecrosis of the Jaw, 2007; ASBMR Task Force on Atypical Femoral Diaphyseal Fractures, 2009; Executive positions: President, Australian and New Zealand Bone and Mineral Society, 1999-2001; Councilor and Board Member, Endocrine Society of Australia, 2006-present; Board Member, Osteoporosis Australia, 2006-present; Chair, Victorian State Committee, Royal Australasian College of Physicians, 2006-present; Member, Scientific Advisory Council, Bio21 Cluster, Melbourne, Australia, 2005-present

Current Research: Health implications of vitamin D deficiency, osteoporosis in men, post-transplant bone disease, particularly after bone marrow transplantation; diabetes and bone, and other secondary causes of osteoporosis; bone anabolic therapies.

Statement of Interest: As a Professor of Medicine in The Department of Medicine (RMH/WH), University of Melbourne and Head of Endocrinology, at Western Hospital, Victoria, Australia I am responsible for training young scientists and clinician scientists in research into musculoskeletal diseases, including several international post-doctoral Fellows and PhD students. I believe the American Society of Bone and Mineral Research provides outstanding opportunities to encourage mentorship and international research collaborations, in addition to its most important role as a forum for leading international bone and mineral research. I joined ASBMR in 1988 whilst working as a Clinical Research Fellow in Endocrinology at Mayo Clinic, Rochester, USA, and I have regularly attended the Meetings from 1989. This year I acted as Clinical Co-Chair of the 31st American Society of Bone Mineral Research Meeting in Denver, Colorado. Over the years I have been fortunate to receive strong and enduring mentorship from Drs. Jack Martin, Larry Riggs, Larry Raisz, Elizabeth Shane, Graham Russell and John Bilezikian to name some influential figures. As an ASBMR Councilor, I will be committed to fostering the interest of younger members of our Society to make their ASBMR experience as rewarding and enjoyable as it has been for me over the years.

I am very experienced in the peer review process and I have served on the Editorial Board of *Journal of Bone and Mineral Research* since 2001 and have been an Associate Editor since 2008. In 2007, I was a member of the ASBMR Task Force on Osteonecrosis of the Jaw. Recently, I was one of 25 Australians appointed to the prestigious Australian National Health and Medical Research Council (NHMRC) "Academy", specifically to represent musculoskeletal diseases and sports medicine research. The NHMRC is the NIH equivalent in Australia. These peer review positions have provided much valuable experience, which will be both extremely relevant and useful for my role as ASBMR Councilor. I would be very keen to promote the recognition of the ASBMR as a truly international scientific society and I would encourage the concept of holding joint meetings with other international bone and mineral research societies, when appropriate. This would both increase the ASBMR membership base and enhance the international profile of ASBMR.

As the Honorary Medical Director of Osteoporosis Australia, a non-government organization, and Chair of its Medical and Scientific Committee, I am experienced in public service. I also serve a Councilor of The Endocrine Society of Australia; and I am a past-President of the Australian and New Zealand Bone and Mineral Society. I continue to be active in research with over 130 peer-reviewed publications, including in *New England Journal of Medicine*, *Science*, *Proceedings of the National Academy of Science (USA)* and *Journal of Bone and Mineral Research*.

It would be an honor and privilege to serve my fellow ASBMR members on ASBMR Council from 2010-2013 and to help advance the already outstanding record of ASBMR.

Disclosures: Amgen 1, 2; Merck and Co., Inc. 1,2; Novartis 1; sanofi-aventis 2; IOF/*Osteoporosis International* 6 (Editorial Board)

The following numerical key was used to characterize the potential conflicts of interest listed in the "Disclosures" section above.

1. *research grants or financial support from commercial entities*
2. *consultant or member of advisory board to a commercial entity*
3. *participant in a speakers bureau*
4. *employment or executive positions in pharmaceutical, medical device, or diagnostic companies*
5. *stock holdings in pharmaceutical, medical device, or diagnostic companies*
6. *any other situation or transaction in relation to the ASBMR in which a formal role or interest exists (e.g., candidate is a member of another bone-related organization's board, or committee, or serves on its journal, etc.)*



HOROWITZ, MARK Professor and Vice Chair for Research, Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, New Haven, Connecticut, USA

Place of Birth: New York, New York, USA

Education/ Training/ Positions: BS, Syracuse University, New York, 1972; PhD, State University of New York (SUNY) at Upstate Medical Center, Syracuse, New York, 1977; Research Associate, Howard Hughes Medical Institute, Yale University School of Medicine, 1977-1979; Postdoctoral Fellowship, Yale University School of Medicine, 1979-1981; Research Associate and Associate Research Scientist, Yale University School of Medicine, 1981-1985; Assistant,

Associate and Professor, Department of Orthopaedics and Rehabilitation, Yale University School of Medicine, 1985-present; Co-Director, Yale Core Center for Musculoskeletal Disorders, 1999-present; Vice Chair for Research, 2006-present

Honors and Awards: ASBMR Young Investigator Award, 1985; Swebilius Cancer Research Award, 1985; Andrew W. Mellon Foundation Award, 1986-1988; Honorary Masters Degree, Yale University, 2001

Editorial duties/ Peer Review Panels: Editorial Boards: *Calcified Tissue International*, 1990-1998; *Journal of Dental Research*, 2000; NIH Special Review Committee for Specialized Centers of Research on Osteoporosis (SCOR), 1987; VA Merit Reviewer, 1987, 1992, 1993; National Cancer Institute Special Review Committee, Program Project, 1988; Grant Reviewer, United States-Israel Binational Science Foundation, 1990; Grant Reviewer, Basic Research Foundation, Israel Academy of Sciences and Humanities, 1991, 1993, 1997, 2002; Member, NIH Special Review Committee for Multipurpose Arthritis Center Grant, 1993; Ad Hoc Member, NIH Orthopaedic and Musculoskeletal Study Section, 1993; Ad Hoc Member, NIH Oral Biology and Medicine Study Section 2, 1993; Member, NIH Special Review Committee, Program Project Grant, 1993; Member, NIH Oral Biology and Medicine Study Section 2, 1994-1998; Member, U.S. Army Medical Research and Material Command, Osteoporosis Scientific Program Committee, 1996; Chairman, NIH Oral Biology and Medicine Study Section 2, 1997-1998; Member, NIH Special Emphasis Panel, RO-3, 1999; Member, NIH Special Emphasis Panel, RO-1, 2001, 2002; Grant Reviewer, The Wellcome Trust, 2002; Member, NIH Special Emphasis Panel, Basic and Applied Stem Cell Research, 2002; Grant Reviewer, National Science Foundation, 2002; External Reviewer, University of Connecticut Core Center, 2002, 2003; Ad Hoc Member, NIH SBDD Study Section, 2003; Grant Reviewer, Orthopaedic Research and Education Foundation, 2005; Chairman, NIH Special Emphasis Panel, SBDD Study Section, 2006-2008; Ad Hoc Member, NIH Fogarty International Research Collaboration Award Study Section, 2008; ASBMR Abstract Reviewer, 2007-2009; Challenge Grants Panel 21, NIH, 2009; Editor, *Osteoimmunology: Interactions of the Immune and Skeletal Systems*, 2009-present

Professional Societies: Membership: ASBMR, 1992-present; Orthopaedic Research Society, 1989-present; Member, ASBMR Industry Relations Committee, 1998; Chairman, ASBMR Fellowship Task Force, 1999; ASBMR Council, 2005-2008; International Society for Stem Cell Research Conference, 2005-present; Chair, International Conference on Osteoimmunology: Interactions of the Immune and Skeletal Systems, 2006, 2008; Member, Finance Committee, Federation of American Societies for Experimental Biology (FASEB), 2008-present

Current Research: Defining the interactions between the skeletal, hematopoietic and immune systems, osteoimmunology. More specifically, analysis of the regulatory interactions controlled by transcription factors first identified as being important for B lymphocyte differentiation but are now known to be important in skeletal development and body composition. How do these transcription factors regulate mesenchymal cell lineage allocation to bone or adipose tissue? The identity, origin and function of marrow adipocytes.

Statement of Interest: I have just finished (September 2008) my three-year term as Councilor of the American Society for Bone and Mineral Research (ASBMR). As part of my responsibilities as Councilor, I reviewed the financial statements of the Society. Early on, it was apparent to me that our investment company, Mercantile-Safe Deposit and Trust Company, was not providing appropriate returns on the Society's investment portfolio (\$7,500,000). I brought my concerns to Council, and as it turned out, the Executive Committee had its own issues with Mercantile that centered on Mercantile's failure to respond in a timely fashion to the Council's direction. The result was firing Mercantile and hiring Chris Jackson of UBS Financial Services. Although I was not alone in my questioning of Mercantile's effectiveness, I believe my input was valuable to Council. It is important for any association or society to carefully manage their reserves and this is especially true for scientific societies, particularly in these times of reduced grant support to their members and in the current economic downturn. Income produced from reserves could make the difference between providing the services the society's membership needs or reducing those services. This means striking a balance between conservative core investments to insure the life of the society and more aggressive positions so as to achieve a total return that meets the needs of the society's membership.

Because of my interest in the financial management of ASBMR, I was the Council representative to the Finance Committee of ASBMR, whose major responsibility was to develop the Society's yearly budget. I am presently the ASBMR representative to the Finance Committee of FASEB. I have also served on the ASBMR Industry Relations Committee and was Chairman of the ASBMR Fellowship Task Force. I have been a member of ASBMR for 17 years.

As Vice Chair for Research, I am reviewing and planning the financial health of the research side of my department. As Co-Director of the Yale Core Center for Musculoskeletal Disorders, I had significant input in developing the \$400,000 budget. I design and administer my federal and private grant budgets. My other qualifications include: 1) former treasurer for the RidgeTop Club, a local tennis and pool club with an annual budget of approximately \$500,000; 2) former treasurer of the investment group Ten Guys LLC; 3) I am proud to say that I was until recently the Treasurer of the Hamden High Boys Lacrosse Booster Club with a budget of approximately \$30,000/year.

While learning a great deal about the inner workings of ASBMR, I believe I made a positive contribution to Council, particularly in its financial health. In addition, I believe my interpersonal skills will be an asset for this job. Because of these reasons, my experience and my continued desire to serve the ASBMR membership and move our Society forward, I am committed to doing a first-rate job as Secretary-Treasurer.

Disclosures: Amgen 5; Current Medicine Group 6 (Written monograph supported by a grant from Amgen); Elsevier 6 (Book Contributor/Editor)

The following numerical key was used to characterize the potential conflicts of interest listed in the “Disclosures” section above.

- 1. research grants or financial support from commercial entities*
- 2. consultant or member of advisory board to a commercial entity*
- 3. participant in a speakers bureau*
- 4. employment or executive positions in pharmaceutical, medical device, or diagnostic companies*
- 5. stock holdings in pharmaceutical, medical device, or diagnostic companies*
- 6. any other situation or transaction in relation to the ASBMR in which a formal role or interest exists (e.g., candidate is a member of another bone-related organization’s board, or committee, or serves on its journal, etc.)*



HRUSKA, KEITH A. Professor of Pediatrics, Medicine, and Cell Biology, Washington University, St. Louis, Missouri, USA

Place of Birth: Sidney, Nebraska, USA

Education/Training/Positions: MD, Creighton University, Omaha, Nebraska, 1969; Intern and Resident, Department of Medicine, Cornell University, New York Hospital, Manhattan, New York, 1969-1971; Resident, Department of Medicine, Washington University, St. Louis, Missouri, 1971-1972; National Institutes of Health (NIH) Postdoctoral Fellow in Nephrology, Washington University, 1972-1974; Instructor, Assistant Professor, Associate Professor, and Professor, Departments of Medicine and Cell Biology/Biophysics, Washington University, 1974-present; Director, Renal Division, Barnes Jewish Hospital, Washington University, 1979-1994; Co-Director, Renal Division, Barnes Jewish Hospital, Washington University, 1994-1998; Ira M. Lang Professor of Medicine in Nephrology, Washington University, 1988-2001; Medical Director, Mid-America Transplant Services, St. Louis, Missouri, 1976-present; Member, Bone and Mineral Division, Department of Medicine, Washington University, 1980-present; Professor of Pediatrics, Director of Pediatric Nephrology, Washington University, 2001-present; Founder, Scientific Advisory Board Chairman, and Board of Directors' Medical Advisor, Isto Technologies, 2004-present

Honors/Awards: Alpha Omega Alpha Honor Medical Society, 1969; NIH Fellowship, Washington University, 1972-1973; National Kidney Foundation Fellowship, Washington University, 1974; Established Investigator Award, American Heart Association, 1979-1984; Ira M. Lang Endowed Chair in Nephrology, 1988-2001, American Society for Clinical Investigation, 1984; Association of American Physicians, 1990

Editorial Duties/Peer Review Panels: Editor: *American Journal of Physiology: Renal, Fluid and Electrolyte Physiology*, 1989-1995; *Calcified Tissue International*, 2000-2004; Editorial Boards: *Calcified Tissue International*, 2000-2004; *Journal of Bone and Mineral Research*, 2003-2006; *Bone*, 2004-2007; Member, Orthopedics and Musculoskeletal Studies Study Section, NIH, 1987-1991; Member, General Medicine B (GMB) Study Section, NIH, 1992-1996; Ad Hoc Member, GMB Oral Biology and Medicine and Orthopedics Study Sections, NIH, 1997-2002; Chair, Musculoskeletal Integrated Review Group Boundaries Panel, NIH, 1999-2001; Ad Hoc Member, Pathobiology of Kidney Disease Study Section, NIH, 2003-2004; Ad Hoc Member, Skeletal Biology Development and Disease Study Section, NIH, 2004; Member, Skeletal Biology Development and Disease Study Section, NIH, 2004-present

Professional Societies: Member: ASBMR; American Physiological Society; American Society for Cell Biology; American Society for Clinical Investigation; American Society of Nephrology (ASN); Association of American Physicians; International Bone and Mineral Society; Orthopaedic Research Society; Member,; Chair, Young Investigator Award Committee, ASN, 1998-2000; Secretary Treasurer, ASBMR, 2006-2009

Current Research: Basic bone cell biology; Chronic kidney disease-mineral bone disorder (CKD-MBD); vascular calcification and phosphorus as a cardiovascular risk factor; cartilage bioengineering and bone anabolic factors, especially the bone morphogenetic proteins

Statement of Interest: I have been a member of the Society since its inception and served as Secretary-Treasurer 2006-2009. I was a council member from 1983-1986 and a member of the education Committee, 1983-1988. I am a chapter author of our Primer, and I have served on the editorial boards of the JBMR, Bone and CTI. I have been an Editor of CTI. I am an active investigator in the fields of bone cell biology as described above. My current focus is in the vascular calcification of the CKD-MBD which has contributed to the discovery of phosphorus as a cardiovascular risk factor, through determining its mechanism of action.

I look forward to the opportunity to serve the society as it leads the pursuit of the causes and treatment of metabolic bone disorders and diseases. The Society has matured in its role and supported the development of a strong scientific base in both basic and clinical research. Recently, the Society has witnessed major recent scientific advances and changes in its environment with the economic recession of 2007-8. Also, the emergence of major abuses associated with relationships to industry leading to new rules and scrutiny governing corporate relations and conflict of interest will have new impact on the ASBMR. Our publishing enterprise has been revamped, and our website redone and modernized. During this recent past of significant developments and accomplishments, our revenues have diminished, and our expenses have held steady. As a result, we now struggle to operate a balanced budget. New sources of revenue are required to maintain our vigor, and continue the pursuit of our mission.


There remains much the society should accomplish. Though we have participated in the clinical definition and development of treatments for several of our diseases, much still needs to be done. Osteoporosis is not at the level of public consciousness that it requires, osteoarthritis is poorly understood and undertreated, and osteoporosis is seriously undertreated. These major shortfalls in the public consciousness and in medical practice of our field require the society to take on a new vigorous role in leading the clinical treatment of metabolic bone diseases. While these are not entirely new directions for the ASBMR, they are new areas of

emphasis and can serve to provide invigoration and freshness to the pursuit of conquering our diseases. As I stand for election, I look forward to supporting the ASBMR in its future endeavors, and I am grateful to the Society for the role it has played in my career.

Disclosures: Celgene 2; Fresenius 1; Genzyme 1; Isto Technologies 5; Shire 1, 2; Stryker 2

The following numerical key was used to characterize the potential conflicts of interest listed in the “Disclosures” section above.

1. *research grants or financial support from commercial entities*
2. *consultant or member of advisory board to a commercial entity*
3. *participant in a speakers bureau*
4. *employment or executive positions in pharmaceutical, medical device, or diagnostic companies*
5. *stock holdings in pharmaceutical, medical device, or diagnostic companies*
6. *any other situation or transaction in relation to the ASBMR in which a formal role or interest exists (e.g., candidate is a member of another bone-related organization’s board, or committee, or serves on its journal, etc.)*



JAN DE BEUR, SUZANNE M. Associate Professor of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Place of Birth: Daytona Beach, Florida, USA

Education/Training/Positions: BA, Cornell University, Ithaca, New York, 1986; MD, Cornell University Medical College, NY, New York, 1992; Olser Medical Intern, The Johns Hopkins University School of Medicine, Baltimore, MD, 1992-93; Olser Medical Resident, The Johns Hopkins University School of Medicine, 1993-95; Endocrinology Fellow, The Johns Hopkins University School of Medicine, 1995-98; Instructor of Medicine, The Johns Hopkins University School of Medicine, 1998-99; Assistant Professor of Medicine, The Johns Hopkins University School of Medicine, 1999-2008; Director of Endocrinology, Johns Hopkins Bayview Medical Center, 2002-present; Associate Professor of Medicine, The Johns Hopkins University School of Medicine, 2008-present

Honors/Awards: C.H. Ferguson Scholar, Cornell University, 1982-83; National Honor Society Scholar, 1982-83; Cornell Tradition Fellow, Cornell University, 1984-86; Glew Award for Student Research, The George Washington University School of Medicine, 1988; Edith Se Ville Coale, M.D Scholar, The George Washington University School of Medicine, 1989; NIH-Howard Hughes Medical Institute Research Scholar, 1989-90; Alfred Moritz Michaelis Prize in Medicine, Cornell University Medical College, 1992; Pearl M Stetler, MD Research Award, The Johns Hopkins University School of Medicine, 1997-1998; Clinician Scientist Award, The Johns Hopkins University School of Medicine, 1998; Recognition Award, Progressive Osseous Hyperplasia Association, 2000; Finalist, Junior Faculty Research Award, Johns Hopkins Department of Medicine, 2001, 2002; National Institutes of Health Loan Repayment Awardee, 2002-2006; Best Women's Doctor, *Baltimore Magazine*, 2004; Leadership Award, Task Force on Women's Academic Careers in Medicine, 2004; Women's Leadership Award, Johns Hopkins University, 2009

Editorial Duties/Peer Review Panels: Associate Editor, *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, 6th Edition, 2005-2006; Associate Editor, *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*, 7th Edition, 2007-2008; Editorial Boards: *Journal of Bone and Mineral Research*, 2004-present; *Journal of Clinical Endocrinology and Metabolism*, 2005-present; Review Panels: National Institutes of Health, Skeletal Biology Development and Disease, 2004-2008; National Institutes of Health, Musculoskeletal, Oral and Skin Sciences, 2008; Data Safety Monitoring Committee, National Institute of Dental and Craniofacial Research, National Institutes of Health, 2009-present; American Society of Bone and Mineral Research, Young Investigator Awards Review Committee, 2008; National Kidney Foundation of Maryland, Grant Reviewer, 2008; David M. Levine Excellence in Mentoring Award Selection Committee, 2004-2007; American Society of Bone and Mineral Research, Abstract Reviewer, 2005-2008; The Endocrine Society, Abstract Reviewer, 2007-present

Professional Societies: American Society of Bone and Mineral Research, 1999-present; ASBMR Membership Development Committee, 2005-present; Chair, ASBMR Membership Development Committee, 2007-present; Chair, Task Force on Clinician Outreach, 2009; Member: Advance in Mineral Metabolism (AIMM), 2001-present; Board of Directors, AIMM, 2006-2009; Annual Meeting Steering Committee, The Endocrine Society, 2006-2009; Publications and Communications Committee, Federation of American Societies for Experimental Biology (FASEB), 2006-2009; Editor in Chief Advisory Committee, *FASEB Journal*, 2008-09; Organizing Committee, NIH Rare Skeletal Disorders Meeting, 2008; International Society of Clinical Densitometry; National Kidney Foundation; GCRC Program Director Association; XLH Network, Board of Scientific Directors, 2005-present

Current Research: Both in the lab and in the clinical setting, my work focuses on understanding the molecular basis of phosphate homeostasis, human conditions of disordered phosphate homeostasis and developing therapeutic targets for treatment of these disorders. Ongoing projects include FGF23 signaling and the control of renal phosphate handling, the role of *klotho* in control of phosphate homeostasis and integration of parathyroid hormone and FGF23 action. I am also engaged in studies of the genetic basis and the phenotypic expression of the parathyroid hormone resistance syndromes, pseudohypoparathyroidism 1a and 1b.

Statement of Interest: It is an honor to be nominated to serve on the ASBMR Council by Past-President, Dr. Barbara Kream and I enthusiastically accept this nomination. I welcome the opportunity to be considered for elected leadership in the ASBMR and I pledge to work whole heartedly to achieve its mission to be the "premier society in the field of bone and mineral metabolism through promoting excellence in bone and mineral research, fostering integration of clinical and basic science and facilitating the translation of that science to health care and clinical practice."

I believe in the mission of the ASBMR and have championed its programs my entire professional life. Since I was a fellow, I have regularly participated in the ASBMR Annual Meetings, reviewed abstracts for the Annual Meeting and critiqued manuscripts for the *Journal of Bone and Mineral Research*. I have served as an Associate Editor for the *Primer on Metabolic Bone Disease and Disorders of Mineral Metabolism* (6th and 7th Editions) and on the Editorial Board of the *JBMR*. I have served as ASBMR's representative to the FASEB Publications and Communication Committee. Most significantly, as a member and

then Chair of the Membership Development Committee, I worked to promote diversity within the ASBMR and focused on attracting and retaining young investigators in ASBMR. During my tenure as MDC Chair, I expanded its activities to include meet-the-professor sessions for professional development and increased collaboration with other committees such as the Education Committee and the Women's Committee. Most recently, I have been leading an expert group of ASBMR members to strategically bolster participation of clinicians in the ASBMR and increase the recognition of ASBMR as the premier source of scientific information about bone health among clinicians.

In addition to my past service to the ASBMR, I bring my experience building and leading the Division of Endocrinology at the Johns Hopkins Bayview Medical Center. Of the 550 faculty in the Johns Hopkins Department of Medicine, I am one of three women Division Directors. During my tenure as Division Chief, I have grown the Division from a single faculty member to five full-time and three part-time faculty members, more than 50% of whom are women. Remarkably, each full-time faculty member has garnered NIH and foundation funding and developed an outstanding basic, clinical or translational research program. Research funding in the Division has rapidly grown from no funded research in 2002 to \$6,881,366 total research funding in 2009. Under my leadership, we recently established the Johns Hopkins Metabolic Bone Center, a comprehensive, multidisciplinary center for the care of patients with metabolic bone disease. In its first year, we evaluated over 1500 patients, doubled DXA volumes, bolstered infusion center visits, and implemented a critical pathway for hip fracture patients. These leadership experiences as Division Chief and program builder have prepared me for leadership in ASBMR.

I am dedicated to promoting young investigators and to building diversity in the academic community. Promoting diversity in the ASBMR with respect to gender, nationality, and race will: 1) enhance membership; 2) attract young investigators from diverse backgrounds 3) provide opportunities for recognition and development of all excellent scientists and clinicians. As our profession becomes increasingly diverse, it is imperative to make our society inclusive and attractive to all investigators interested in bone and mineral research. I serve on the Executive Committee of the Task Force on Women's Academic Careers in Medicine at Johns Hopkins University. Through leadership in this group, I developed a mentoring program for women fellows, planned and participated in career-related, educational seminars for fellows and junior faculty, and advised the Chairman of Medicine on the status of women fellows and faculty in the department. I have been recognized for my leadership in this capacity with the Leadership Award from the Johns Hopkins Task Force on Women's Academic Careers in Medicine and The Johns Hopkins Women's Network Leadership Award.

It is truly privilege to be a member of such a successful and thriving society. I embrace the opportunity to apply my past experience and personal and professional strengths to develop new initiatives and support established programs that will increase public awareness of ASBMR's work, attract and retain young investigators in the ASBMR, develop clinical-policy leadership and insure the financial soundness of the society.

Disclosures: Kirin Pharmaceuticals DSMB 2; The Endocrine Society 6 (Annual Meeting Steering Committee); JCEM 6 (Editorial Board)

The following numerical key was used to characterize the potential conflicts of interest listed in the "Disclosures" section above.

1. *research grants or financial support from commercial entities*
2. *consultant or member of advisory board to a commercial entity*
3. *participant in a speakers bureau*
4. *employment or executive positions in pharmaceutical, medical device, or diagnostic companies*
5. *stock holdings in pharmaceutical, medical device, or diagnostic companies*
6. *any other situation or transaction in relation to the ASBMR in which a formal role or interest exists (e.g., candidate is a member of another bone-related organization's board, or committee, or serves on its journal, etc.)*



LANE, NANCY E. Director and Endowed Professor, Aging Center, Medicine and Rheumatology, University of California at Davis Medical Center, Sacramento, California

Place of Birth: Los Angeles, California, USA

Education/Training/Positions: BS, University of California, Davis, Biochemistry, 1976; MD, University of California, San Francisco (UCSF), 1980; Residency in Medicine, San Francisco, CA, 1980-1983; Fellowship as Clinical Fellow in Rheumatology, Stanford University Medical Center, Stanford, CA, 1983-1985; Diplomate, American Board of Internal Medicine, 1983; Diplomate, Subspecialty Board of Rheumatology, 1986; Assistant Professor of Medicine and Rheumatology, UCSF, 1990-1995; Associate Professor of Medicine, UCSF, 1996-2004;

Endowed Professor of Aging, Director Center for Aging, UC Davis School of Medicine, 2005-present

Honors/Awards: Department of Biochemistry Citation, Phi Kappa Phi, University of California, 1976; Western Region, Merck Rheumatology Fellow Award, 1984; Subspecialty Board for Rheumatology, American Board of Internal Medicine, 1984, 1987; Nominated and elected, Executive Leadership in Academic Medicine, 1997; Marilyn S. Singleton Scholarship for Women Leadership in Academic Medicine, 1997; Endowed Professor in Aging, UC Davis, 2004; Ira Goldstein Memorial Lecture, NYU University, March 2007; Honored by ASBMR for USBJD Presidency, 2007; Finalist, Marion Spencer Fay Award, National Board for Women in Medicine and Leadership Institute for Drexel University College of Medicine, 2007-present; Inducted, San Mateo County Women's Hall of Fame, 2008; UC Davis School of Medicine Dean's Award for Research Mentoring, 2008

Editorial Duties/Peer Review Panels: Editorial Boards: *Arthritis and Rheumatism* 1998-present; *Osteoporosis International*, 1999-present; *Journal of Rheumatology*, 1995-present; *Journal of Clinical Rheumatology*, 1995-present; *Journal of Bone and Mineral Research*, 2004-present; *Nature Clinical Practice Rheumatology*, 2007-present; Faculty 1000 of Medicine, 1999-2001; Section Editor, *Osteoporosis Current Rheumatology Reports*, 2002-2007; *Journal of Musculoskeletal Medicine*, 1997-present; Associate Editor: *Arthritis Research and Therapy*, 2007-present; ASBMR *Primer of the Metabolic Bone Diseases*, Editions 4 and 5; Co-Editor, *Arthritis and Rheumatism*, 2005-present; Peer Review Panels: NIAMS Clinical Trial Review, 1994; External Grant Reviewer: Arthritis and Rheumatism Council for Great Britain; Wellcome Trust; Kennedy Institute, 1995-2008; Grant Reviewer: Department of Defense, 1996; NIH/NIAMS Orthopaedic Study Section, 1997-2001; DSMB member, R01AG18397, 2001-present; Chairperson, NIAMS Centers of Excellence in MS Diseases Core Centers, 2006; Grant Reviewer: NIH NIAMS K23 Loan Repayment, and R03 Awards, 2004-2008; NIAMS Go Grand Ad-hoc Study Section, 2009

Professional Societies: ASBMR; Association of Osteobiology; Association of American Physicians; President U.S. Bone and Joint Decade Board of Directors, 2005-2007; ASBMR Representative, Executive Board of Directors, U.S. Bone and Joint Decade, 2005-2009; Co-chair, U.S. Board Joint Decade Organizing Committee, 2009

Current Research: Cell biology of glucocorticoid induced osteoporosis; effects of bone active agents on the localized and whole bone material properties in a rat model of osteoporosis; the epidemiology and genetics of osteoarthritis of the hip and knee; risk factors for osteoporotic fractures; novel therapies to treat osteoporosis

Statement of Interest: Briefly outlined below are my qualifications for the position of ASBMR Councilor. After graduating from the University of California at Davis with a Bachelor's of Science degree in Biochemistry, I completed Medical School at the University of California at San Francisco, Internal Medicine Residency at Mt Zion/UCSF and my rheumatology fellowship at Stanford University Medical Center. During my continuous 20-year involvement in ASBMR, I have been an active participant in a number of committees and other assignments including serving as a member of the In Vivo Bone Research Group from 1994 to present, a member of the abstract selection committee (2002-2004, 2007), full member of the scientific policy committee (2003-2006), ASBMR executive board representative to the U.S. Bone and Joint Decade (2006-2009), Invited Speaker for annual meeting for Grant Writing tips (2003, 2004 and 2005), Inflammatory Bone Loss (2005 and 2006), and Glucocorticoid-induced osteoporosis (2009), In vivo working group invited speaker (2000 and 2009), and moderator of a number of scientific sessions (1994, 2007, 2008 and 2009), and have been a member of ASBMR special task forces for Mentorship Awards and the Harold Frost Young Investigator Awards (2004 and 2007).

The ASBMR Board supported me as a representative to the education and research committee of the USBJD in 2004-2005. The purpose of that committee was to develop a plan to address how to increase the number of clinical investigators performing musculoskeletal research in the US. Working on this subcommittee, with members of the ASBMR and ORS, we initiated the Young Investigators Workshop. As the chair of this USBJD task force, we assembled a committed faculty of approximately 15, senior investigators throughout the United States and Canada and have now had approximately 7 workshops (2 each year: one in the fall and one in the spring), with nearly 90 participants and almost \$25 million in grant funding from peer-reviewed organizations has been obtained. This program has required that I participate in fund raising and we have obtained funding to support this work from the NIH (an R13 and an U13), supporting organizations of the USBJD (including the ASBMR) and pharmaceutical industry support. In addition, the ASBMR supported my nomination as President of the Board for the United States Bone and Joint Decade (2005-2007), and Past-President year (2007-2008), and co-ASBMR representative 2008-2009. During my tenure as the ASBMR representative to the Board of the USBJD, I have been able to further the ASBMR mission of

increasing research in bone diseases, train young investigators in grant writing through USBJD sponsored Young Investigator Grant Writing Workshops, support the development of a musculoskeletal subject examination in medical schools and raise awareness of bone diseases through the development of an action plan for osteoporosis to increase the dissemination of the Surgeon General's Report on Osteoporosis and assisting in the development of the Rare Bone Disease Coalition. These efforts demonstrate my successful experience running committees, working as a team player and completing the mission of the group.

My current position is Director of the Center for Healthy Aging at U.C. Davis Medical Center and Professor of Medicine and Rheumatology. My job has allowed me to recruit and mentor a number of junior faculty in the field of bone metabolism. My laboratory research in bone quality is NIH funded and our work is routinely presented at the annual ASBMR meeting. In addition, our research group has always engaged national and international collaborations with other bone researchers and this has provided me with a solid understanding of the international nature of the ASBMR.

In summary, this statement explains my interest and supports my qualifications for a position on the ASBMR Council. My long standing work in the field of bone metabolism, experience with professional society boards, my deep commitment to working within the ASBMR to promote and grow the organization and young investigators in the field, positions me well to be an effective councilor.

Disclosures: Amgen 2, 3; Eli Lilly and Co. 3; NordicBiosciences/Novartis 1; Pfizer 1; Proctor and Gamble 1

The following numerical key was used to characterize the potential conflicts of interest listed in the "Disclosures" section above.

1. *research grants or financial support from commercial entities*
2. *consultant or member of advisory board to a commercial entity*
3. *participant in a speakers bureau*
4. *employment or executive positions in pharmaceutical, medical device, or diagnostic companies*
5. *stock holdings in pharmaceutical, medical device, or diagnostic companies*
6. *any other situation or transaction in relation to the ASBMR in which a formal role or interest exists (e.g., candidate is a member of another bone-related organization's board, or committee, or serves on its journal, etc.)*



ORWOLL, ERIC S. Professor of Medicine; Director, Oregon Clinical and Translational Research Institute; Associate Dean for Clinical and Translational Research, School of Medicine; Associate Vice-President for Research, Oregon Health and Science University, Portland, Oregon, USA

Place of Birth: Wyandotte, Michigan, USA

Education/Training/Positions: BS, University of Michigan, Ann Arbor, 1970; MD, University of Maryland School of Medicine, Baltimore, 1974; Medicine Resident, Providence Medical Center, Portland, Oregon, 1974-1977; Post-doctoral Fellow in Endocrinology, Oregon Health & Science University, 1977-79; *Portland VA Medical Center positions:* Associate Investigator, Research

Service, 1979-1980; Staff/Attending Physician, Endocrinology, 1979-present; Director, Endocrinology Clinic, 1980-1998; Attending Physician in Medicine, 1982-1998; Chief, Section of Endocrinology and Metabolism, 1985-1998; *Oregon Health & Science University positions:* Research Fellow, Endocrinology and Metabolism, 1977-1979; Assistant Professor of Medicine, 1979-1984; Attending Physician, Endocrinology, 1979-present; Associate Professor of Medicine, 1985-1996; Director, Bone and Mineral Clinic/Bone Densitometry Services, 1986-2006; Director, Bone and Mineral Research Unit, 1986-2006; Head, Bone and Mineral Section, Division of Endocrinology, Diabetes, Clinical Nutrition, 1990-2006; Deputy Chief, Division of Endocrinology, Diabetes, Clinical Nutrition, 1990-1998; Professor of Medicine, 1996-present; Assistant Dean for Research, 1997-2002; Chair, Research Committee, School of Medicine, 1997-2006; Director, General Clinical Research Center, 1998-2006; Associate Dean for Clinical and Translational Research, 2002–present; Assistant Vice President for Research, 2002–2006; Associate Vice President for Research, 2006-present; Director, Oregon Clinical and Translational Research Institute, 2006-present

Honors/Awards: Associate Investigator, Veterans Administration Career Development Grant Award, 1979; Research Associate, Veterans Administration Career Development Grant Award, 1980; John Kendall Senior Research Award, Portland VA Medical Center, 1990;

Editorial Duties/Peer Review Panels: Editorial Boards: *Journal of Bone and Mineral Research*, 1992-2002; *Journal of Clinical Densitometry* (JCD) 1997-present; Associate Editor, *JCD*, 2002 -2006; *Journal of Clinical Endocrinology and Metabolism*, 1997-2001; *Current Osteoporosis Reports*, 2003-2006; *The Journal of Men's Health & Gender*, 2003-2006; *Journal of Clinical Endocrinology and Metabolism*, 2004-2006; *Endocrinology*, 2004-2006; *Bone*, 2007-present; Reviewer: *Endocrinology*, *Annals of Internal Medicine*; *Journal of Clinical Endocrinology and Metabolism*; *Archives of Internal Medicine*; *Bone*; *Journal of Bone and Mineral Research*; *Calcified Tissue International*, Hormone and Metabolic Research; Osteoporosis International; *American Journal of Clinical Nutrition*; *European Journal of Clinical Investigation*; *Journal of Clinical Investigation*; *American Journal of Medicine*; Proceedings of the National Academy of Sciences; *JAMA*; *New England Journal of Medicine*; Member, Orthopedics Study Section, National Institutes of Health

Professional Societies: ASBMR: American Federation for Clinical Research; Western Society of Clinical Investigation; Western Association of Physicians; Endocrine Society; American Society for Clinical Nutrition; Federation of American Societies for Experimental Biology; Fellow, American College of Physicians; Program Co-Chair, American Society for Bone and Mineral Research Annual Meeting, 2004

Current Research: Major areas of investigation have been in osteoporosis in men, and the role of sex steroids in the regulation of bone metabolism. Current clinical studies include the epidemiology and clinical character of bone disorders in men, and the evaluation of therapies for osteoporosis in men. Other interests include the elucidation of pathophysiological mechanisms of metabolic bone disease and the discovery of new therapeutic and diagnostic tools for the clinical care of patients with osteoporosis. Dr. Orwoll is also actively involved in studies of the genetic determinants of skeletal phenotypes in human populations, and in the investigation of genes that affect bone mass, geometry and material properties in the mouse. The interplay of these two lines of investigation, bone genetics in mice and men, provide interesting opportunities for translational research. Principle investigator of several research studies funded by the National Institutes of Health, including the Study of Osteoporotic Fractures in Men (MrOS)

Statement of Interest: After being a member of ASBMR for about 25 years and having been involved in the Society in a variety of ways I find myself more and more interested in helping with its governance. I have some experience that would be useful, including being a member of ASBMR committees, a member of the JBMR Editorial Board, a Clinical Program Chair for the Annual ASBMR Meeting, and having stood on many ASBMR podiums as an investigator, invited speaker and moderator. In addition to my experience with the Society, I have had some experience as an investigator, from the bench, in translational research, and in population studies, and I maintain several ROIs, UOI and foundation grants. I have worked extensively with industry partners in a variety of situations, and have been involved in FDA reviews. I am very experienced in NIH issues as an investigator and member of committees, conferences, etc. Finally, I have most recently been very involved in the research leadership of an academic health center, and am the principle investigator of the Oregon CTSA. If I can help, I am very interested in contributing.

Disclosures: Amgen 1, 2; Eli Lilly & Co. 1, 2; GTx 2; Merck and Co., Inc. 1, 2

The following numerical key was used to characterize the potential conflicts of interest listed in the “Disclosures” section above.

- 1. research grants or financial support from commercial entities*
- 2. consultant or member of advisory board to a commercial entity*
- 3. participant in a speakers bureau*
- 4. employment or executive positions in pharmaceutical, medical device, or diagnostic companies*
- 5. stock holdings in pharmaceutical, medical device, or diagnostic companies*
- 6. any other situation or transaction in relation to the ASBMR in which a formal role or interest exists (e.g., candidate is a member of another bone-related organization’s board, or committee, or serves on its journal, etc.)*



ROODMAN, G. DAVID Professor of Medicine; Vice Chair for Medicine Research; Director, Myeloma Program; Director, Center for Bone Biology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Place of Birth: Louisville, Kentucky, USA

Education/Training/Positions: BA, The Johns Hopkins University, Baltimore, Maryland, 1969; MD, University of Kentucky College of Medicine, Lexington, Kentucky, 1973; PhD, University of Kentucky, 1975; Intern in Medicine, University of Kentucky, 1975-1976; Resident in Medicine, University of Minnesota, Minneapolis, MN, 1976-1978; Fellow in Hematology, University of Minnesota, 1978-1980; Research Associate, University of Minnesota, 1978-1980; Assistant Professor, Associate Professor, Professor of Medicine, and Associate Chair for Research, University of Texas Health Science Center at San Antonio (UTHSCSA), Texas, 1980-2001; Staff Physician, Director of Hematology Clinic, and Chief of Hematology Section, Audie Murphy Veterans Administration Hospital, San Antonio, Texas, 1981-2001; Associate Scientist, Biomedical Research Foundation of South Texas, 1986-2001; Director, Bone Biology Center, University of Pittsburgh Medical Center, Pittsburgh, PA, 2001-present; Director, Myeloma Program, University of Pittsburgh Cancer Institute, 2001-present; Professor of Medicine, University of Pittsburgh School of Medicine, 2001-present; Vice Chair for Research, Department of Medicine, University of Pittsburgh School of Medicine, 2002-present

Honors/Awards: Delta Phi Alpha, 1969; Clinical Investigator, Veterans Administration, 1988-1993; The Paget Foundation Research Award, 1989; American Society for Clinical Investigation, 1991; The Paget Foundation Research Award, 1993; Association of American Physicians, 1996; Dr. Bernard G. and Rhoda Sarnat Lectureship in Bone Biology for Contribution to Advancement of Science in the State of Israel, 2000; The Paget Foundation Research Award, 2002; John B. Johnson Award for Research in Paget's Disease, 2002; Pittsburgh Magazine "Top Doctor" list, 2005-2009; Louis V. Avioli Founders Award for Basic Research in Bone, 2007

Editorial Duties/Peer Review Panels: Editorial Boards: *Experimental Hematology*, 1991-present; *Bone*, 1993-present; *Journal of Clinical Investigation*, 1998-present; *Endocrinology*, 2001-present; *Experimental Biology and Medicine*, 2006-present; Associate Editor, *Journal of Bone and Mineral Research*, 2002-2008; Review Panels: American Heart Association Grant Reviewer, 1984-1989; VA Merit Review Board-Hematology, 1987-1990; National Osteoporosis Foundation Grant Reviewer, 1987-present; Ad Hoc Reviewer, NIH, Oral Biology and Study Section, 1991-1993; Osteoclast Abstract Reviewer, ASBMR 2000-present; International Myeloma Foundation Grant Reviewer, 2001-Present; The Israel Science Foundation (ISF) Grant Reviewer, 2002; Multiple Myeloma Research Foundation (MMRF) Grant Reviewer, 2004-present; NIH, Program Project Reviewer, 2005; USAMRMC Bone Health & Military Medical Readiness Report Reviewer, 2005; New England Journal of Medicine Textbook Reviewer, 2005; SRA, Skeletal Biology Structure & Regeneration Study Section, 2005-present; VA Research Scientific Evaluation Committee 2009

Professional Societies: Memberships: American Society of Hematology, 1980-present; International Society for Experimental Hematology, 1982-present; American Association for the Advancement of Science, 1983-present; American Society for Bone and Mineral Research, 1984-present; Council of the American Federation for Clinical Research, 1986-1989; American Society for Clinical Investigation, 1990-present; International Bone and Mineral Society, 1991-present; Association of American Physicians, 1996-present; The Endocrine Society, 2002-present; American Society for Biochemistry and Molecular Biology, 2006-present; Counselor, Southern Society for Clinical Investigation, 1993-1998; Nominating Committee, ASBMR, 1994-1995; Nominating Committee, Int'l Society for Experimental Hematology, 1995-1998; Advocacy Committee, ASBMR, 1999-2004; Paget's Foundation Board Member, 2001-2004; MMRF Scientific Advisory Board Member, 2001-2004; Advisory Council of the NIH Osteoporosis and Related Bone Diseases, 2001-present; Scientific Advisory Board of the International Myeloma Foundation, 2001-present; Scientific Program Committee, ASBMR, 2002; Member, International Bone and Mineral Society Publications Committee, 2002-present; Strategic Advisor, Scios Inc., Developing Myeloma Therapeutics and Innovative Therapies, 2003; Consultant, NIH, Osteoporosis and Related Bone Disease, National Resource Center, 2003; Co-Chair, National Cancer Institute's "Think Tank," The Tumor Microenvironment, 2003; Chairman for the Paget Foundation, 2006-present; Member of the ASH Ad Hoc Scientific Committee on Plasma Cell Biology, 2007-present

Current Research: Focuses on the role of osteoclasts in normal and pathologic conditions such as Paget's disease and multiple myeloma. We are evaluating the potential utility of blocking ADAM8 and $\alpha_v\beta_1$ integrin, as therapeutic targets for decreasing the bone destruction in rheumatoid arthritis and the contribution of osteoclasts in stimulating angiogenesis in myeloma and solid tumor bone metastases. In addition, we have developed in vivo models of Paget's disease to determine the contribution of environmental and genetic factors to the development of Paget's disease. Most recently, we demonstrated that GFI-1 is responsible in part for osteoblast suppression in myeloma and are now determining if blocking GFI-1 expression reverses bone destruction and osteoblast suppression in myeloma models.

Statement of Interest: I am very interested in becoming a councilor for the ASBMR because I want to continue my active involvement in the society and keep the ASBMR as the outstanding society for bone research. I have been involved in the ASBMR since 1981 when I attended the ASBMR meeting in San Antonio. Since that time, I have participated as an abstract

reviewer on multiple occasions, was on the Advocacy Committee for 5 years, served as an Associate Editor for the Journal of Bone and Mineral Research, and participated at the new investigator meetings and symposia such as AIMM. Through the efforts of the Journal of Bone and Mineral Research and ASBMR, the importance of bone research has become appreciated by scientists and laymen outside of the bone field, as evidenced by the increasing numbers of bone related presentations at the American Society of Hematology and the American Society of Clinical Oncology, societies that were previously unaware of or did not highlight the importance of bone research. One of the most important functions of the ASBMR is to mentor young investigators; and as councilor, I plan to continue to promote the AIMM Meeting, which I think is a very important forum for young investigators to present and network with established investigators, and to develop new initiatives that further enhance young investigators' research. Young investigators have to be made aware of other sources of funding outside of the NIH in order to maintain their laboratories until the current funding climate changes. Without these types of activities, the ranks of the next generation of bone researchers will be severely depleted. In addition, I think that it is very important that the society foster interactions with other societies beyond the bone field. In particular, the rheumatologic societies and the cancer societies are all important interactions that need to be pursued and enhanced. Equally important are the advocacy activities of the ASBMR, which have to be continued and strengthened to help both established and young investigators obtain grant support in this highly competitive era of NIH funding as well as to make the public more aware of bone health issues. Continuing to bring outstanding investigators from outside the bone field to the ASBMR meeting is yet another important area that must be maintained. State-of-the-art symposia highlighting cutting-edge technologies and discoveries have become a feature of the ASBMR annual meeting. Developing seminars on how these discoveries can be adapted to the bone field is an important goal for the continued progress in bone research. I hope to continue to increase these programs. Finally, to continue ASBMR as an international society, I would work to strengthen our interactions with bone researchers/societies in other parts of the world including Eastern Europe and South America and hold joint meetings and co-sponsor meetings focused on important areas in bone research

Disclosures: Novartis Pharmaceuticals 1, 2, 3; Amgen 2; Celgene 2; Acceleron 2; Millennium 2

The following numerical key was used to characterize the potential conflicts of interest listed in the "Disclosures" section above.

1. *research grants or financial support from commercial entities*
2. *consultant or member of advisory board to a commercial entity*
3. *participant in a speakers bureau*
4. *employment or executive positions in pharmaceutical, medical device, or diagnostic companies*
5. *stock holdings in pharmaceutical, medical device, or diagnostic companies*
6. *any other situation or transaction in relation to the ASBMR in which a formal role or interest exists (e.g., candidate is a member of another bone-related organization's board, or committee, or serves on its journal, etc.)*